|Day Low/High||271.06 / 277.28|
|52 Wk Low/High||223.02 / 333.65|
Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2017 financial results, including: Total revenues of $2.
U.S. stock futures rise and European shares are mostly higher as global markets rally in the wake of Emmanuel Macron's victory in the first round of France's presidential elections.
When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.
Biogen (NASDAQ:BIIB) will present Phase 3 end of study SPINRAZA ® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in...
Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA ® (dimethyl fumarate) and TYSABRI ® (natalizumab), early in the course...
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Biogen (NASDAQ: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorization...
Biogen (NASDAQ: BIIB) will present data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the 69th annual meeting of the American...
Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...
Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.
In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
Biogen (NASDAQ: BIIB) will present data from its Alzheimer's and Parkinson's disease programs at the 13 th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria March 29 -...
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open.
Wall Street could be in for a rocky week in the wake of the Republicans' failure to repeal and replace Obamacare as promised.
European stocks drifted lower Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.
European stocks are expected to open mixed Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.
Wall Street ends with modest gains in a week in which the Federal Reserve decided to pull the trigger on an interest rate hike.
Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.
Stocks rise on Friday even as a selloff in health care extends into its second day.